Fintel reports that on April 20, 2023, Keybanc upgraded their outlook for Health Catalyst (NASDAQ:HCAT) from Sector Weight to Overweight .
Analyst Price Forecast Suggests 28.19% Upside
As of April 6, 2023, the average one-year price target for Health Catalyst is $16.58. The forecasts range from a low of $14.14 to a high of $21.00. The average price target represents an increase of 28.19% from its latest reported closing price of $12.93.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Health Catalyst is $304MM, an increase of 10.13%. The projected annual non-GAAP EPS is -$0.24.
What are Other Shareholders Doing?
HSLAX - THE HARTFORD SMALL CAP GROWTH FUND holds 100K shares representing 0.18% ownership of the company. No change in the last quarter.
Jane Street Group holds 122K shares representing 0.22% ownership of the company. In it's prior filing, the firm reported owning 162K shares, representing a decrease of 32.57%. The firm decreased its portfolio allocation in HCAT by 24.05% over the last quarter.
Quent Capital holds 8K shares representing 0.01% ownership of the company. No change in the last quarter.
JNL SERIES TRUST - JNL holds 8K shares representing 0.01% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 1,368K shares representing 2.45% ownership of the company. No change in the last quarter.
What is the Fund Sentiment?
There are 386 funds or institutions reporting positions in Health Catalyst. This is a decrease of 20 owner(s) or 4.93% in the last quarter. Average portfolio weight of all funds dedicated to HCAT is 0.16%, an increase of 22.42%. Total shares owned by institutions decreased in the last three months by 8.37% to 58,581K shares. 
The put/call ratio of HCAT is 1.20, indicating a bearish outlook.
Health Catalyst Background Information
(This description is provided by the company.)
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform-powered by data from more than 100 million patient records and encompassing trillions of facts-as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
See all Health Catalyst regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
